Fig. 2: PRMT5 inhibitors restore chemo-sensitivity of NPC cells.

A the effect of combined PRMT5 inhibitor and PTX treatment on cell proliferation, as shown by colony formation assay. The PTX concentration used was 2 nmol/L, and the concentration of EPZ015666 (EPZ) and GSK591 concentration were 3 μmol/L. The same concentrations of PRMT5 inhibitors and PTX were used in the other experiments, unless otherwise stated. Left, representative images; Right, quantification. Data are shown as means ± SD (n = 3). ***P < 0.001.B the growth curve of 5-8FR cells treated with PRMT5 inhibitors, with or without PTX, at different time points. Cell viability was assessed using CellTiter-Glo reagent. Data are shown as means ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. C Tumorsphere formation assay of 5-8 F R cells under different treatments for 8 days. Scale bars, 200 μm. Representative images (Left) and quantifications (Right). Data are shown as means ± SD (n = 3). ***P < 0.001. D Sub-G1 population analysis in 5-8 F R cells treated with PRMT5 inhibitors, PTX or both for 96 h. Data are shown as means ± SD (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. E Annexin-V-PI staining to assess the apoptotic ratios of 5–8 F R cells under different treatments. Cells were collected after 96 h of treatment. Results shown are representative images from three experiments. F Western blot analysis of PRMT5 and H3R2me2s expression in 5-8 F R cells under different treatment. EPZ015666 (EPZ).